Business
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
- 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage - 31% Overall Response Rate (ORR): 4 of 13 patients with > 2
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"- 100% Disease Control Rate (DCR): 16 of 16 evaluable patients demonstrate tumor shrinkage\n - 31% Overall Response Rate (ORR): 4 of 13 patients with > 2 post-baseline scans had a confirmed Partial Response (PR); no patients have come off-treatment prior to the 2nd scan\n - 46% of patients (6 of 13) with > 2 post-baseline scans observed >30% tumor shrinkage, including an unconfirmed PR awaiting next tumor assessment\n - Manageable side effect profile observed with darovasertib and crizotinib combination at the Phase 2 expansion dose, with predominantly Grade 1 or 2 drug-related adverse events\n - Darovasertib and crizotinib expansion dose selected for potential registrational studies\n - Investor Day webcast and conference call scheduled for this morning, December 7, 2021 at 8:30 am ET, to present darovasertib and crizotinib Phase 1/2 clinical efficacy and tolerability\n\n\nSOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients.\n\n \n \n \n \n \n \n\n \n\"The partial responses, percentage of patients with tumor shrinkage and disease control rate observed from the darovasertib and crizotinib synthetic lethal combination in heavily pre-treated MUM patients represents a new clinical efficacy benchmark and provides an opportunity to deliver meaningful patient impact in this high unmet medical need patient population,\" said Meredith McKean, M.D., Sarah Cannon Research Institute at Tennessee Oncology, Associate Director, Melanoma and Skin Cancer Research.\n\"These data provide clinical proof-of-concept for the PKC and cMET synthetic lethal combination, and further validate IDEAYA's synthetic lethality platform. We look forward to exploratory evaluation of this novel PKC and cMET synthetic lethal combination in other potential tumor settings, including GNAQ/11 skin melanoma and MET-amplified and MET high expression tumors,\" said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.\nThere are currently no FDA approved therapies for metastatic uveal melanoma or GNAQ/GNA11...